STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE II HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE II HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to shrink liver tumors before surgery
Disease control OngoingThis study tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. About 4 adults with early-stage but high-risk liver cancer…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New drug combo aims to stop liver cancer return after surgery
Disease control OngoingThis study tests whether giving two drugs (atezolizumab and bevacizumab) before surgery can help prevent liver cancer from coming back. It involves 16 adults with liver cancer that can be surgically removed. The drugs work by boosting the immune system and blocking tumor blood su…
Matched conditions: STAGE II HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:32 UTC